Epilepsy Research

YKP3089C021: An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects with Partial Onset Seizures

Sponsor

SK Life Science Inc.

Phase of Development

Phase III

Study Duration

12 week titration phase followed by an open label maintenance phase

Enrollment Status

Open

Principal Investigator

Joanne B. Rogin, MD

A0081096:  A Prospective, Randomized, 12-week, Controlled Study of Visual Field Change in Subjects with Partial Seizures Receiving Pregabalin or Placebo

Sponsor

Pfizer, Inc.

Phase of Development

Phase IV

Study Duration

15 weeks

Enrollment Status

Open

Principal Investigator

Joanne B. Rogin, MD

SP0982/EP0012:   A double-blind, randomized, placebo-controlled, parallel-group, adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathic generalized epilepsy.

Sponsor

UCB Biosciences, Inc.

Phase of Development

Phase III

Study Duration

36 weeks

Enrollment Status

Open

Principal Investigator

Joanne B. Rogin, MD

N01379:  An open-label, multi-center, follow-up study to evaluate the long-term safety and efficacy of brivaracetam used as adjunctive treatment in subjects aged 16 years or older with epilepsy.

Sponsor

UCB Biosciences, Inc.

Phase of Development

Phase III

Enrollment Status

Closed

Principal Investigator

Joanne B. Rogin, MD

Research Contact: Katelynn Rehs, Clinical Research Coordinator 763-302-4035 Katelynn.Rehs@mpls-clinic.com

Important Information:
A description of all the clinical trials stated above are available on https://clinicaltrials.gov/, as required by U.S. Law.

All epilepsy clinical trials being conducted at the Minneapolis Clinic of Neurology are approved by an independent ethics committee called an Institutional Review Board (IRB).  An IRB is a type of committee used in research in the United States that has been formally designated to approve, monitor, and review biomedical and behavioral research involving human subjects.  The purpose of the IRB is to assure that appropriate steps are taken to protect the rights and welfare of human subjects participating in a research study.